{"id":262547,"date":"2026-09-23T09:11:58","date_gmt":"2026-09-23T03:41:58","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=262547"},"modified":"2026-09-23T09:11:58","modified_gmt":"2026-09-23T03:41:58","slug":"aurobindo-pharma-vs-astrazeneca-pharma-india-vs-bal-pharma","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-vs-astrazeneca-pharma-india-vs-bal-pharma\/","title":{"rendered":"Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma: Which Stock Should You Track"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Aurobindo Pharma PE 26.31, mkt cap Rs 97,642 crore. AstraZeneca Pharma India PE 98.93, mkt cap Rs 16,780 crore. Bal Pharma PE 23.97, mkt cap Rs 174 crore.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma is a side-by-side comparison of three companies from the Pharmaceuticals space. On this comparison, Aurobindo Pharma carries a market capitalisation of about Rs 97,642 crore against Rs 16,780 crore for AstraZeneca Pharma India and Rs 174 crore for Bal Pharma, with return on equity of 9.25%, 21.49% and 7.64% respectively. Each company&#8217;s numbers are presented here without a declared better pick, since the right stock depends on an investor&#8217;s own criteria.<\/p>\n<\/div>\n<p>Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma starts with the core numbers most investors compare within the Pharmaceuticals segment: market capitalisation, valuation multiples, profitability and dividend yield. Figures below are sourced as of September 2026 and will shift with daily price moves.<\/p>\n<p>All three names sit in the Pharmaceuticals bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses.<\/p>\n<p style=\"margin-top:24px;\"><strong>Tap to Access Best Research Pieces on Univest<\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-vs-astrazeneca-pharma-india-vs-bal-pharma\/#Aurobindo_Pharma_AstraZeneca_Pharma_India_and_Bal_Pharma_Company_Overview\" title=\"Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma: Company Overview\">Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma: Company Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-vs-astrazeneca-pharma-india-vs-bal-pharma\/#Aurobindo_Pharma_vs_AstraZeneca_Pharma_India_vs_Bal_Pharma_Valuation_and_Profitability_Snapshot\" title=\"Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma: Valuation and Profitability Snapshot\">Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma: Valuation and Profitability Snapshot<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-vs-astrazeneca-pharma-india-vs-bal-pharma\/#Aurobindo_Pharma_vs_AstraZeneca_Pharma_India_vs_Bal_Pharma_Latest_Quarterly_Results\" title=\"Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma: Latest Quarterly Results\">Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma: Latest Quarterly Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-vs-astrazeneca-pharma-india-vs-bal-pharma\/#What_Should_Investors_Look_at_Beyond_These_Numbers\" title=\"What Should Investors Look at Beyond These Numbers?\">What Should Investors Look at Beyond These Numbers?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-vs-astrazeneca-pharma-india-vs-bal-pharma\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-vs-astrazeneca-pharma-india-vs-bal-pharma\/#FAQs_on_Aurobindo_Pharma_vs_AstraZeneca_Pharma_India_vs_Bal_Pharma\" title=\"FAQs on Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma\">FAQs on Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-vs-astrazeneca-pharma-india-vs-bal-pharma\/#What_is_the_market_cap_difference_between_Aurobindo_Pharma_AstraZeneca_Pharma_India_and_Bal_Pharma\" title=\"What is the market cap difference between Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma?\">What is the market cap difference between Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-vs-astrazeneca-pharma-india-vs-bal-pharma\/#Which_of_the_three_has_the_highest_PE_ratio\" title=\"Which of the three has the highest PE ratio?\">Which of the three has the highest PE ratio?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-vs-astrazeneca-pharma-india-vs-bal-pharma\/#Which_of_the_three_has_the_highest_ROE\" title=\"Which of the three has the highest ROE?\">Which of the three has the highest ROE?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-vs-astrazeneca-pharma-india-vs-bal-pharma\/#Which_of_these_three_stocks_pays_the_highest_dividend_yield\" title=\"Which of these three stocks pays the highest dividend yield?\">Which of these three stocks pays the highest dividend yield?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-vs-astrazeneca-pharma-india-vs-bal-pharma\/#What_is_the_debt_to_equity_ratio_for_Aurobindo_Pharma_AstraZeneca_Pharma_India_and_Bal_Pharma\" title=\"What is the debt to equity ratio for Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma?\">What is the debt to equity ratio for Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-vs-astrazeneca-pharma-india-vs-bal-pharma\/#Which_of_the_three_trades_at_the_highest_price_to_book_value\" title=\"Which of the three trades at the highest price to book value?\">Which of the three trades at the highest price to book value?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-vs-astrazeneca-pharma-india-vs-bal-pharma\/#Is_one_of_Aurobindo_Pharma_AstraZeneca_Pharma_India_or_Bal_Pharma_better_than_the_others\" title=\"Is one of Aurobindo Pharma, AstraZeneca Pharma India or Bal Pharma better than the others?\">Is one of Aurobindo Pharma, AstraZeneca Pharma India or Bal Pharma better than the others?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Aurobindo_Pharma_AstraZeneca_Pharma_India_and_Bal_Pharma_Company_Overview\"><\/span><strong>Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma: Company Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Aurobindo Pharma<\/strong> is a listed Indian company in the Pharmaceuticals space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.<\/p>\n<p><strong>AstraZeneca Pharma India<\/strong> is a listed Indian company in the Pharmaceuticals space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.<\/p>\n<p><strong>Bal Pharma<\/strong> is a listed Indian company in the Pharmaceuticals space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Aurobindo_Pharma_vs_AstraZeneca_Pharma_India_vs_Bal_Pharma_Valuation_and_Profitability_Snapshot\"><\/span><strong>Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma: Valuation and Profitability Snapshot<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Aurobindo Pharma<\/th>\n<th>AstraZeneca Pharma India<\/th>\n<th>Bal Pharma<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Market Cap (approx.)<\/td>\n<td>Rs 97,642 crore<\/td>\n<td>Rs 16,780 crore<\/td>\n<td>Rs 174 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio (TTM)<\/td>\n<td>26.31<\/td>\n<td>98.93<\/td>\n<td>23.97<\/td>\n<\/tr>\n<tr>\n<td>PB Ratio<\/td>\n<td>2.58<\/td>\n<td>19.23<\/td>\n<td>2.11<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity (ROE)<\/td>\n<td>9.25%<\/td>\n<td>21.49%<\/td>\n<td>7.64%<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM, Rs)<\/td>\n<td>64.49<\/td>\n<td>67.85<\/td>\n<td>4.55<\/td>\n<\/tr>\n<tr>\n<td>Dividend Yield<\/td>\n<td>0.24%<\/td>\n<td>0.54%<\/td>\n<td>1.10%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.21<\/td>\n<td>0.13<\/td>\n<td>1.94<\/td>\n<\/tr>\n<tr>\n<td>Book Value per Share (Rs)<\/td>\n<td>658.53<\/td>\n<td>349.12<\/td>\n<td>51.65<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"margin-top:24px;\"><strong>Check the Univest Screener for Live Data<\/strong><\/p>\n<p>On valuation, Aurobindo Pharma trades at a PE of 26.31 and a PB of 2.58, AstraZeneca Pharma India at a PE of 98.93 and a PB of 19.23, while Bal Pharma trades at a PE of 23.97 and a PB of 2.11. On return on equity, the three post 9.25%, 21.49% and 7.64% respectively, and on dividend yield they stand at 0.24%, 0.54% and 1.10%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Aurobindo_Pharma_vs_AstraZeneca_Pharma_India_vs_Bal_Pharma_Latest_Quarterly_Results\"><\/span><strong>Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma: Latest Quarterly Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Company<\/th>\n<th>Latest Quarter Revenue<\/th>\n<th>Latest Quarter Net Profit<\/th>\n<th>YoY Change (Revenue)<\/th>\n<th>QoQ Change (Revenue)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Aurobindo Pharma<\/td>\n<td>Rs 9,414.58 crore<\/td>\n<td>Rs 1,032.03 crore<\/td>\n<td>+18.1%<\/td>\n<td>+5.0%<\/td>\n<\/tr>\n<tr>\n<td>AstraZeneca Pharma India<\/td>\n<td colspan=\"4\">Quarterly revenue and profit figures for AstraZeneca Pharma India were not independently verified this round; readers should check the company&#8217;s latest exchange filing before relying on a quarter-specific figure.<\/td>\n<\/tr>\n<tr>\n<td>Bal Pharma<\/td>\n<td>Rs 89.06 crore<\/td>\n<td>Rs 1.14 crore<\/td>\n<td>+33.7%<\/td>\n<td>+6.2%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Quarterly figures above are the most recent reported quarter for each company (Q1 FY28, quarter ended June 2026), compared with the year-ago and preceding quarter where that data was available. A blank cell means the figure could not be independently verified in this pull and should be checked on the company&#8217;s own exchange filing before use.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <strong>Univest iOS App<\/strong> or <strong>Univest Android App<\/strong> to track Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma live prices.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Should_Investors_Look_at_Beyond_These_Numbers\"><\/span><strong>What Should Investors Look at Beyond These Numbers?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Beyond the metrics above, investors comparing these three pharmaceuticals names should track quarter-on-quarter revenue and margin trends, management commentary on order books or demand, and any sector-specific regulatory or input-cost developments, since a single-quarter snapshot can shift quickly.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma highlights how differently three companies in the same pharmaceuticals segment can score across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information as of September 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Aurobindo_Pharma_vs_AstraZeneca_Pharma_India_vs_Bal_Pharma\"><\/span><strong>FAQs on Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_market_cap_difference_between_Aurobindo_Pharma_AstraZeneca_Pharma_India_and_Bal_Pharma\"><\/span><strong>What is the market cap difference between Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of September 2026, Aurobindo Pharma has a market cap of approximately Rs 97,642 crore, AstraZeneca Pharma India is at approximately Rs 16,780 crore, and Bal Pharma is at approximately Rs 174 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_of_the_three_has_the_highest_PE_ratio\"><\/span><strong>Which of the three has the highest PE ratio?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Among Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma, the PE ratios stand at 26.31, 98.93 and 23.97 respectively as of September 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_of_the_three_has_the_highest_ROE\"><\/span><strong>Which of the three has the highest ROE?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma post ROE of 9.25%, 21.49% and 7.64% respectively as of September 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_of_these_three_stocks_pays_the_highest_dividend_yield\"><\/span><strong>Which of these three stocks pays the highest dividend yield?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma carry dividend yields of 0.24%, 0.54% and 1.10% respectively.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_debt_to_equity_ratio_for_Aurobindo_Pharma_AstraZeneca_Pharma_India_and_Bal_Pharma\"><\/span><strong>What is the debt to equity ratio for Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Aurobindo Pharma carries a debt to equity of 0.21, AstraZeneca Pharma India of 0.13, and Bal Pharma of 1.94.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_of_the_three_trades_at_the_highest_price_to_book_value\"><\/span><strong>Which of the three trades at the highest price to book value?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma trade at price to book ratios of 2.58, 19.23 and 2.11 respectively.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_one_of_Aurobindo_Pharma_AstraZeneca_Pharma_India_or_Bal_Pharma_better_than_the_others\"><\/span><strong>Is one of Aurobindo Pharma, AstraZeneca Pharma India or Bal Pharma better than the others?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This comparison does not declare one stock better than another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor&#8217;s own criteria and research.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the market cap difference between Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of September 2026, Aurobindo Pharma has a market cap of approximately Rs 97,642 crore, AstraZeneca Pharma India is at approximately Rs 16,780 crore, and Bal Pharma is at approximately Rs 174 crore.\"}},{\"@type\":\"Question\",\"name\":\"Which of the three has the highest PE ratio?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Among Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma, the PE ratios stand at 26.31, 98.93 and 23.97 respectively as of September 2026.\"}},{\"@type\":\"Question\",\"name\":\"Which of the three has the highest ROE?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma post ROE of 9.25%, 21.49% and 7.64% respectively as of September 2026.\"}},{\"@type\":\"Question\",\"name\":\"Which of these three stocks pays the highest dividend yield?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma carry dividend yields of 0.24%, 0.54% and 1.10% respectively.\"}},{\"@type\":\"Question\",\"name\":\"What is the debt to equity ratio for Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Aurobindo Pharma carries a debt to equity of 0.21, AstraZeneca Pharma India of 0.13, and Bal Pharma of 1.94.\"}},{\"@type\":\"Question\",\"name\":\"Which of the three trades at the highest price to book value?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma trade at price to book ratios of 2.58, 19.23 and 2.11 respectively.\"}},{\"@type\":\"Question\",\"name\":\"Is one of Aurobindo Pharma, AstraZeneca Pharma India or Bal Pharma better than the others?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This comparison does not declare one stock better than another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor's own criteria and research.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma compared on market cap, PE, PB, ROE, dividend yield and debt to equity, as of September 2026.<\/p>\n","protected":false},"author":29,"featured_media":262546,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[6686,1019],"class_list":["post-262547","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-pharmaceuticals","tag-stock-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["262546"],"rank_math_title":["Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma: Compa"],"rank_math_description":["Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma compared on market cap, PE, PB, ROE, dividend yield and debt to equity, as of September 2026."],"rank_math_focus_keyword":["Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/09\/aurobindo-pharma-vs-astrazeneca-pharma-india-vs-bal-pharma-which-stock-should.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/262547","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=262547"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/262547\/revisions"}],"predecessor-version":[{"id":262548,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/262547\/revisions\/262548"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/262546"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=262547"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=262547"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=262547"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}